Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286062 · ClinicalTrials.gov registry record · Phase 1
VM110 in Detection of Microscopic Tumors: A Phase I Study
A Phase 1 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03286062: Clinical Trial Phase 1 study, sponsored by Fox Chase Cancer Center.
NCT03286062 is a Phase 1 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03286062, a Phase 1 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage so that patients can get treatment early and prevent the disease from advancing to late stage leading to fatality or recurrence.
Primary Outcome
Patients would be monitored for severity of adverse events due to VM110 based on NCI CTCAE criteria 4.03
Interventions
- COMBINATION_PRODUCT Agent VM110 and laproscopic infra-red probe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-10-12 |
| Est. Completion | 2020-04-03 |
| Phase | Phase 1 |
Why NCT03286062 stopped before completion
NCT03286062 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Agent VM110 and laproscopic infra-red probe is the first listed.
NCT03286062 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03286062 about?
NCT03286062 is a clinical study titled "VM110 in Detection of Microscopic Tumors: A Phase I Study". A laproscopic imaging tecgnology that uses a synthetic agent to detect ovarian and pancreatic cancers at an early stage so that patients can get treatment early and prevent the disease from advancing to late stage leading to fatality or recurrence.
What is the current status of trial NCT03286062?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2017-10-12. Estimated completion is 2020-04-03.
What interventions are being tested in trial NCT03286062?
The interventions under investigation include: Agent VM110 and laproscopic infra-red probe (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03286062?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03286062's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI